Next Vial vs Lean Meds
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Lean Meds
Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy
Visit Lean Meds →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, Lean Meds opens cheaper — $79/mo against $249.97, and Lean Meds finishes ahead, 9.3 to 5.8. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
Next Vial
Starting monthly rate for GLP-1 program; tirzepatide rate not published.
Lean Meds
Standing month-to-month rate. The advertised $69 is the 12-month prepay tier; 3-month is $76 and 6-month is $73.
Standing month-to-month rate. Prepay tiers: $105 for 3 months, $100 for 6, $95 for 12.
What’s included
Next Vial
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Lean Meds
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
Next Vial
5.8/10
Lean Meds
9.3/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | Next Vial | Lean Meds |
|---|---|---|
| Starting Price | $249.97/mo | ✓$79/mo |
| Features | 7 features | 7 features |
| States Available | 49 | ✓50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About Next Vial
An online marketplace that connects patients to licensed providers for compounded semaglutide and tirzepatide injections, microdose options included. It is LegitScript verified and names its dispensing pharmacy: Manifest Pharmacy in Greer, SC. There is no membership required, and one price covers the consultation, the medication and free shipping. It serves 49 states.
Read our full Next Vial review →About Lean Meds
Titrating up does not raise the rate, which is flat and monthly: $79 to start on compounded semaglutide, $109 on compounded tirzepatide, the telehealth visit and shipping absorbed into both. Clinicians come from the OpenLoop Health network. Trinity HealthCare Supply, LLC operates the service and puts names to its five dispensing pharmacies as well as to the physicians who prescribe.
Read our full Lean Meds review →Pros & Cons
Next Vial
What we like
- Semaglutide at $249.97 a month, within the normal band around this register's $189 median for the same drug and form
- The monthly figure covers medication, consult, shipping
- Coverage is published for 49 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Lean Meds
What we like
- Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
- Tirzepatide at $109 a month, 59% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- Names 5 dispensing pharmacies, which most sellers in this register do not do
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Lean Meds takes it, 9.3 against 5.8, and it is especially strong on knowing which pharmacy fills the vial — it names Belmar Pharmacy. Next Vial is no weak second and may fit you better on compounded semaglutide at $249.97/month.
Choose Next Vial if…
You want compounded semaglutide at $249.97/month and an opening price near $249.97 a month.
Choose Lean Meds if…
You want knowing which pharmacy fills the vial — it names Belmar Pharmacy and an opening price near $79 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →Found
Tirzepatide at $169/month, 37% under the register median
From $99/mo
Get started →Next Vial vs Lean Meds: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Next Vial and Lean Meds head-to-heads in the same category.
- Next Vial vs Trimi Health
- Next Vial vs Embody
- Next Vial vs He & She MD
- Lean Meds vs NextMeds
- Lean Meds vs bmiMD
- Lean Meds vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.